Researchers evaluated the microbial characteristics driving ankylosing spondylitis pathogenesis, and they examined the effects of tumor necrosis factor inhibitor therapy on the microbiome.
Researchers assessed and compared the risk for chronic kidney disease in men and women with ankylosing spondylitis in China.
Researchers evaluated the risk for obstructive sleep apnea among patients with ankylosing spondylitis.
Heritability and familial risk for ankylosing spondylitis were compared between Swedish cohorts and cohorts in other countries.
The FDA has approved Avsola (infliximab-axxq; Amgen), a biosimilar to Remicade (infliximab; Janssen Biotech).
Researchers investigated the efficacy and safety of ixekizumab for up to 52 weeks in patients with active radiographic axial spondyloarthritis who were biologic disease-modifying antirheumatic drug-naive or tumor necrosis factor inhibitor-experienced.
In a phase 3 study, researchers assessed the efficacy and safety of ixekizumab in patients with active nonradiographic axial spondyloarthritis.
Tumor necrosis factor inhibitors slow radiologic progression when compared to other drug classes in ankylosing spondylitis.
Researchers aimed to identify factors related to depressive symptoms in ankylosing spondylitis and comprehend their underlying associations.
Researchers compared the prevalence of gout in a population of patients with ankylosing spondylitis vs the general population.
